Skip to main content
Caplight Logo









Spirovant Sciences

Spirovant Sciences

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://spirovant.com/

Last Round

Grant

Jan 23, 2019

Total Funding Raised

$4.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Spirovant Sciences is a biotechnology company that develops gene therapies for cystic fibrosis and other respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

CF treatmentcystic fibrosis treatmentgene therapyAAV gene therapymutation-agnostic therapyCFTR gene therapyadeno-associated virusAAVrespiratory disease therapyinhaled gene therapyaerosol-delivered therapyclinical-stage companyOrphan Drug DesignationRare Pediatric Disease Designationgene delivery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spirovant Sciences Comparables

Compare Spirovant Sciences with similar companies based on industry and business-model similarity.

Spirovant Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ReCode Therapeutics
87%
cystetic Medicines
83%
4DMT
82%

Spirovant Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 23, 2019

Key People

Founding team and executive leadership

David Whitwell

Chief Financial Officer

Executive Team

Spirovant Sciences Investors

Notable investors and investment history

Spirovant Sciences investors
InvestorRounds
Emily's EntourageSeed
Militia Hill VenturesSeed
Cystic Fibrosis FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 336% MoM.

  • Apr 1, 2026

    Monthly visitors increased 63% MoM.

Spirovant Sciences Filings

Explore SEC and related filing metadata, where available.

Spirovant Sciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Spirovant Sciences's valuation, stock price, and market status.

Is Spirovant Sciences a public or private company?

Spirovant Sciences is a private company.

What is the current stock price of Spirovant Sciences?

Spirovant Sciences is a private company with no public stock price. No recent secondary market data is available.

How much is Spirovant Sciences worth (valuation)?

Valuation information for Spirovant Sciences is not publicly available.

Can I buy Spirovant Sciences stock?

Spirovant Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Spirovant Sciences's last funding round?

Spirovant Sciences's most recent funding round was Grant on January 23, 2019.

Who are the main investors in Spirovant Sciences?

Key investors in Spirovant Sciences include Emily's Entourage, Cystic Fibrosis Foundation.

Will Spirovant Sciences IPO soon?

No public IPO plans have been announced for Spirovant Sciences.

How can I track Spirovant Sciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Spirovant Sciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range15
Year Founded2016
Last FundingJan 23, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?